Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults
Status:
RECRUITING
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is the second single ascending dose study of L608 in healthy participants and is being conducted to evaluate the safety of L608 with higher dose levels, starting from 20 μg and escalating up to a planned maximum dose of 110 μg.